Shares of Illumina (ILMN) surged 5.28% during intraday trading on Thursday, following the release of the company's second fiscal quarter earnings report after the previous day's close.

The positive market reaction came as Illumina posted another quarter of above-consensus results, extending a streak of strong performance. The company's recent track record includes a 9.52% EPS beat in Q1, a 10.2% beat in Q4, and a full-year revenue guidance range that topped analyst estimates. Additionally, the board authorized a $1.5 billion stock buyback program, further boosting investor confidence.

Analyst sentiment has grown increasingly bullish, with firms like JPMorgan and Daiwa Securities issuing upgrades in recent months. RBC highlighted that the company's mid-teens clinical growth, driven by oncology testing and screening applications, appears sustainable over the next one to two years, reinforcing the optimistic outlook for the stock.